title: Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.
abstract: Ezrin is a cytoskeleton linker protein that is actively involved in the metastatic process of cancer cells. We have searched for a prognostic value of ezrin and some of its partners: alpha-smooth muscle actin and CD44H in 37 patients with an osteosarcoma. Automate immunohistochemistry (IHC) with anti-ezrin, alpha-smooth muscle actin and CD44H antibodies was performed in 66 specimens: 37 biopsies before chemotherapy, 16 resected tumours of "poor" responders and 13 metastases. The messenger RNA (mRNA) levels of ezrin of 13 frozen biopsies and 4 metastases were evaluated by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR). All results were correlated to the following clinical data. Ezrin expression by IHC was found in 62% of 37 biopsies in the different histological subtypes. A good correlation was found between positive or negative samples by IHC and mRNA levels. Ezrin expression was recorded in 84.5% of metastastic samples. The mean expression of ezrin was higher in metastases than biopsies (p = 0.024). In multivariate analysis, ezrin was an independent prognostic marker for event-free survival and overall survival (OS) with p < 0.001 and p = 0.003, respectively, and alpha-smooth muscle actin for OS only (p = 0.024). Our findings suggest that ezrin and alpha-smooth muscle actin are predictive IHC prognostic markers for patients with an osteosarcoma.
authors.affiliation: Service d'Oncologie Médicale Adulte CHU Timone, APHM, Marseilles, France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Salas
authors.forename: Catherine
authors.initials: C
authors.lastname: Bartoli
authors.forename: Jean-Laurent
authors.initials: JL
authors.lastname: Deville
authors.forename: Jean
authors.initials: J
authors.lastname: Gaudart
authors.forename: Fréderic
authors.initials: F
authors.lastname: Fina
authors.forename: Arlette
authors.initials: A
authors.lastname: Calisti
authors.forename: Gérard
authors.initials: G
authors.lastname: Bollini
authors.forename: Georges
authors.initials: G
authors.lastname: Curvale
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Gentet
authors.forename: Florence
authors.initials: F
authors.lastname: Duffaud
authors.forename: Dominique
authors.initials: D
authors.lastname: Figarella-Branger
authors.forename: Corinne
authors.initials: C
authors.lastname: Bouvier
mesh_terms: D000199:Actins / Q000235:genetics / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism; D001859:Bone Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D003598:Cytoskeletal Proteins / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005602:France / Q000453:epidemiology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000378:metabolism; D009362:Neoplasm Metastasis / Q000473:pathology; D012516:Osteosarcoma / Q000378:metabolism* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D012333:RNA, Messenger / Q000378:metabolism; D015996:Survival Rate; D000099149:Ezrin